Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease (Q35978022)

11 August 2017

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease (English)

1 reference

11 August 2017

1 reference

1 reference

1 reference

Seymour MT

1

1 reference

11 August 2017

Mansi JL

2

1 reference

11 August 2017

Gallagher CJ

3

1 reference

11 August 2017

Gore ME

4

1 reference

11 August 2017

Harper PG

5

1 reference

11 August 2017

Evans TR

6

1 reference

11 August 2017

Edmonds PM

7

1 reference

11 August 2017

Slevin ML

8

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 1994

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

69

1 reference

11 August 2017

1

1 reference

11 August 2017

191-195

1 reference

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Phase II study of daily oral etoposide in refractory germ cell tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Epirubicin for pretreated advanced ovarian cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Doxorubicin and Cyclophosphamide, Alternated with Bleomycin and Mitomycin C as a Second-Line Regimen in Advanced Ovarian Carcinoma Resistant to Cisplatin-Based Chemotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968773

A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry

24 September 2018

1 reference

12 December 2020

Phase II trial of VP-16-213 in advanced ovarian carcinoma

1 reference

12 December 2020

Variable bioavailability following repeated oral doses of etoposide

1 reference

12 December 2020

Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies

1 reference

12 December 2020

A phase II study of mitozantrone in advanced carcinoma of the ovary

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Hexamethylmelamine as a single second-line agent in ovarian cancer

1 reference

12 December 2020

Chronic daily administration of oral etoposide

1 reference

12 December 2020

Low-dose oral etoposide: a new role for an old drug?

1 reference

12 December 2020

Low-dose oral etoposide in epithelial cancer of the ovary

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.33

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

8286205

1 reference